Livmoniplimab

Livmoniplimab (ABBV-151) is a monoclonal antibody against GARP/TGF-β1 that can inhibit the release of active TGF-β1. Livmoniplimab has anti-tumor activity in colon cancer mice. Livmoniplimab can be used for the study of locally advanced or metastatic solid tumors[1][2].

Product Specifications

CAS Number

[2412004-88-5]

Product Name Alternative

ABBV-151; ARGX-115

UNSPSC

12352203

Target

TGF-beta/Smad

Type

Inhibitory Antibodies

Related Pathways

Stem Cell/Wnt; TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/livmoniplimab.html

Purity

99.25

Solubility

10 mM in DMSO

Smiles

[Livmoniplimab]

Molecular Weight

(146.22 kDa)

References & Citations

[1]Tindall RR, et al. The TGF-β superfamily as potential therapeutic targets in pancreatic cancer. Front Oncol. 2024 Mar 4;14:1362247. |[2]Guo J, et al. A novel GARP humanized mouse model for efficacy assessment of GARP-targeting therapies. Int Immunopharmacol. 2024 Mar 30;130:111782.